Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study of OR502 Alone and in Combination With Other Anti-cancer Agents in Subjects With Advanced Malignancies

NCT06090266 is registered in ClinicalTrials.gov with OncoResponse, Inc. as lead sponsor.

NCT NCT06090266
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06090266 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study of OR502 Alone and in Combination With Other Anti-cancer Agents in Subjects With Advanced Malignancies
Lead sponsor
OncoResponse, Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
October 24, 2023
Completion date
February 1, 2027
Enrollment
168 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, cancer, cutaneous melanoma, malignant neoplasm, metastatic cancer, non-small cell lung cancer, tumor, solid